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Background: Cholinesterase inhibitors (ChEIs) such as donepezil have the effect of delaying progression of
Alzheimer’s disease (AD), but their effect on life expectancy is unclear. We analyzed the influence of donepezil on
life expectancy after onset of AD, together with the effects of antipsychotic drugs and residency in a nursing home.
Methods: All outpatients at the Tajiri Clinic from 1999–2012 with available medical records and death certificates
were included in a retrospective analysis. The entry criteria were a dementia diagnosis based on DSM-IV criteria
and diagnosis of AD using NINCDS-ADRDA criteria; medical treatment for more than 3 months; and follow up
until less than 1 year before death.
Results: We identified 390 subjects with medical records and death certificates, of whom 275 had a diagnosis of
dementia that met the entry criteria. Of 100 patients diagnosed with AD, 52 had taken donepezil and 48 patients
had not received the drug due to treatment prior to the introduction of donepezil in 1999 in Japan. The lifetime
expectancies after onset were 7.9 years in the donepezil group and 5.3 years in the non-donepezil group. There
was a significant drug effect with a significant covariate effect of nursing home residency. Other covariates did
not reach a significant level.
Conclusions: Although this report has the limitation of all retrospective analyses: the lack of randomization, we
found a positive effect of donepezil on lifetime expectancy after onset of AD. This may be due to a decreased
mortality rate caused by reduction of concomitant diseases such as pneumonia. The similar life expectancies in
patients taking donepezil at home and those not taking donepezil in a nursing home indicated a positive health
economic effect of the drug.
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Several longitudinal studies have shown that cognitive
impairment with advancing age is a negative predictor of
subsequent survival [1]. This association remains after
adjusting for medical conditions and self-rated health,
and thus has been attributed to the effects of decreased
biological vitality [2]. However, it has also been suggested
that the cognition-mortality link reflects more than just a
reduction in biological vitality. Systematic reviews have
concluded that the terminal decline is a multifactorial* Correspondence: k-meg@umin.ac.jp
1Division of Geriatric Behavioral Neurology, CYRIC, Tohoku University, Sendai,
Miyagi 980-8575, Japan
2The Osaki-Tajiri SKIP Center, Osaki, Miyagi 989-4413, Japan
© 2014 Meguro et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.phenomenon, with origins that operate across the entire
lifespan [3].
Higher levels of cognition are associated with better
health literacy and higher socioeconomic status, and lead
to better health management and reduced mortality.
Education is positively associated with access to health
services, increased likelihood of correctly following
instructions for use of medication, and better chronic
disease management [4]. Health literacy may, therefore,
result in earlier diagnosis and earlier intervention, thus
reducing disease impact on cognitive development over
the lifespan. Alternatively, possible positive effects of psy-
chosocial activities such as exercise and mental activities
may be decreased by cognitive impairment. In addition tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Meguro et al. BMC Neurology 2014, 14:83 Page 2 of 6
http://www.biomedcentral.com/1471-2377/14/83these effects, dementia itself is a risk factor for decreased
life expectancy.
Life expectancy for patients with dementia directly
influences prevalence and service needs and is a com-
mon question posed by families and patients. A recent
[5] systematic review compared mortality and survival in
dementia with estimated life expectancies in the general
population. Survival after diagnosis of dementia varies
considerably and depends on numerous factors and
complex interactions among these factors. Relative loss
of life expectancy decreases with age at diagnosis and
also depends on gender, dementia subtype, and severity
stage. A definitive meta-analysis of survival in dementia
is precluded by deficiencies in primary studies.
Alzheimer’s disease (AD) is the main cause of dementia.
At present, there are no curative drugs for AD; however,
symptomatic drugs such as cholinesterase inhibitors
(ChEIs) or memantine may delay progression of the dis-
ease. This effect combined with psychosocial interventions
may increase quality of life (QOL) [6]. Beyond delayed
progression and increased QOL, the ultimate outcome
of drug treatment should be measured in terms of life
expectancy.
ChEIs such as donepezil are used for symptomatic treat-
ment of AD. Treatment with these drugs can delay nursing
home placement [7], reduce the caregiver burden and the
time spent caring [8], and possibly reduce mortality for pa-
tients living in nursing homes [9] and in the community
[10]. However, the effect on mortality is uncertain: Lopez
et al. [10] found that ChEIs can delay a move to a nursing
home, but have no effect on life expectancy, whereas a re-
cent cohort study [11] in 7,073 AD patients in the Swedish
Dementia Registry suggested that ChEIs were associated
with a lower risk of death and myocardial infarction.
These associations were stronger with increasing ChEI
dose, which may be due to the vagotonic and antiin-
flammatory effects of these drugs on atherosclerosis.
In this study, we examined whether donepezil has an
effect on life expectancy in AD. We hypothesized that 1)
the drug has a positive effect on life expectancy in AD,
2) that nursing home residency also has a positive effect,
and 3) that use of antipsychotic drugs has a negative
effect. We analyzed donepezil alone because in Japan this
drug has been used since 1999, whereas other drugs such
as galantamine or memantine have only been used since
2011. The combined effect of donepezil and nursing home
residency was also analyzed. Although the retrospective
design, this is the long-term study of the possible effect of
donepezil on life expectancy of patients with AD.
Methods
Patients
All patients were outpatients at the memory clinic at the
Osaki-Tajiri SKIP Center or residents at the Kagobo-no-sato nursing home, which is associated with the Osaki-
Tajiri SKIP Center. All nursing home patients received
medical services at the memory clinic. Outpatients and
nursing home patients all underwent magnetic reson-
ance imaging (MRI) to confirm the medical diagnosis of
dementia. Chest X-ray, electrocardiogram, and blood
tests were performed to exclude possible systemic dis-
eases that could affect cognitive functions. The entry
criteria were 1) a dementia diagnosis based on DSM-IV
criteria, a Clinical Dementia Rating (CDR) [12] of 1+,
and diagnosis of dementing diseases using the estab-
lished criteria described below; 2) medical treatment for
more than 3 months; and 3) follow up until less than
1 year before death.
Dementia diagnosis
Diagnoses of the following diseases were made at a meet-
ing of two neurologists, a psychiatrist, and a physician.
1) Pure AD without cerebrovascular diseases
(CVD) was diagnosed in patients who met
NINCDS-ADRDA criteria for probable AD [13]
and had no CVD on MRI. On MRI, low signal
intensity on T1-weighted images, high signal
intensity on T2-weighted images, and high signal
intensity surrounding the low signal intensity
areas on FLAIR images were considered to
show CVD.
2) AD with CVD was diagnosed based on
NINCDS-ADRDA criteria for probable AD
and on evidence for the presence of CVD
on MRI; however, CVD lesions were judged
to be concomitant with AD and not responsible
for cognitive deterioration.
3) VaD was diagnosed based on NINDS-AIREN
criteria for probable VaD [14].
4) Dementia with Lewy bodies (DLB)/ Parkinson
disease with dementia (PDD) and frontotemporal
lobar degeneration (FTLD) were diagnosed based
on the respective consensus criteria [15,16].
5) Others conditions were diagnosed in 20 patients
with head trauma (n = 3), hydrocephalus (n = 3),
diabetic dementia (n = 2), vitamin B12 deficiency
(n = 2), thyroid dysfunction (n = 2), progressive
supranuclear palsy (n = 1), alcoholic dementia
(n = 1), chronic subdural hematoma (n = 1), hepatic
encephalopathy (n = 1), renal encephalopathy (n = 1),
hypoxic encephalopathy (n = 1), syphilis (n = 1), and
brain tumor (n = 1).
Analyses
The main outcome was the time (months) between
onset of AD and death. Age at the first clinic visit, gender,
presence of concomitant CVDs, use of antipsychotic drugs
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analyzed as covariates.
One-way Analysis of Variance (ANOVA) was performed
to analyze the drug effect with the covariate effects. A
Spearman correlation was calculated between the period
of donepezil administration and life expectancy.
Written informed consent was obtained from each of
the patients and from the family of those with dementia
at entry according to the Declaration of Helsinki (BMJ
1991; 302: 1194). The study was approved by the ethical
committee of Tohoku University Graduate School of




A total of 390 medical records and death certificates
were available for the period 1999–2012, including 275
patients with diagnoses of dementia that met the entry
criteria. The number of patients with each dementing
disease is shown in Figure 1. The most common disease
was VaD, followed by AD and AD with CVD. Of the 100
patients with AD and AD with CVD (both of which are
diseases that can be treated with donepezil), 52 received
donepezil and 48 patients did not receive the drug due
to treatment prior to the introduction of donepezil in
1999 in Japan.
Demographics and causes of deaths
The patients who received donepezil (DNP group, n = 52)
included 18 men and 34 women, and had a mean (SD)
age of 80.5 (6.9) years old and a mean score on the
Mini-Mental State Examination (MMSE) of 14.1 (6.3).
The patients who did not receive donepezil (non-DNP
group, n = 48) included 10 men and 38 women, and had a
mean age of 82.9 (6.7) years old and a mean MMSE scoreFigure 1 Numbers of patients with different dementing
diseases. VaD = vascular dementia, AD = Alzheimer’s disease,
CVD = cerebrovascular diseases, DLB = dementia with Lewy bodies,
PDD = Parkinson disease with dementia, MCI = mild cognitive
impairment, FTLD = frontotemporal lobar degeneration. The vertical
line indicates the numbers.of 14.1 (6.8). Thus, there was no significant difference
in the male-to-female ratio, age or MMSE score be-
tween the two groups. The two groups also had a
similar distribution of causes of death (Table 1), with
pneumonia and respiratory failure being the main causes
in each group.Effect on life expectancy
The life expectancies after onset were 7.9 years in the
DNP group and 5.3 years in the non-DNP group (Figure 2).
There was a significant drug effect with a significant co-
variate effect of nursing home residency. Other covariates
did not reach a significant level.
Spearman analysis showed a significant positive correl-
ation between the period of donepezil use and life ex-
pectancy in AD (Figure 3).
Since there was a significant effect of nursing home
residency on life expectancy, the patients were classified
into 4 groups: those taking donepezil and living in a nurs-
ing home (DNP + NH group) or at home (DNP + non-NH
group), and those not taking donepezil and living in a nurs-
ing home (non-DNP + NH group) or at home (non-DNP +
non-NH group). The demographics of these groups are
shown in Table 2. There were no group differences for
men/women ratio and mean age.
As shown in Figure 4, life expectancy was increased by
nursing home residency, in addition to the donepezil
treatment effect.Discussion
This report demonstrates the possible effect of donepezil
on life expectancy after onset of AD. This possible effect
was found to be independent of age, gender, and the use
of antipsychotic drugs. Before discussing the results, we
should note methodological limitations.Table 1 Demographics and causes of death for DNP and
non-DNP groups
DNP group Non-DNP group
n (men/women) 52 (18/34) 48 (10/38)
Mean age (SD), years 80.5 (6.9) 82.9 (6.7)
Causes of death
Pneumonia and/or respiratory failure 19 21
Cancer 1 4
Stroke 3 3




There were no group differences for men/women ratio, causes of deaths
(chi-square tests) and mean age (t-test).
Figure 2 Donepezil effect on life expectancy in AD. DNP =
donepezil, AD = Alzheimer’s disease. The vertical line indicates life
expectancy (months). There was a significant drug effect (F = 14.497;
p < 0.001) with a significant covariate effect of nursing home
residency (F = 18.167. p < 0.001). No other covariates reached a
significant level (age: F = 0.075, p = 0.785; gender: F = 0.171, p = 0.680;
CVD: F = 3.827, p = 0.054; typical antipsychotic drugs: F = 0.353, p = 0.554;
atypical antipsychotic drugs: F = 0.583, p = 0.447).









N 10 42 14 34
Men/Women 1/9 17/25 2/12 8/26
Age (mean) 80.2 80.6 82.9 82.9
(SD) 8.8 6.5 6.4 6.8
DNP = donepezil, NH = nursing home.
There were no group differences for men/women ratio (chi-square tests) and
mean age (one-way ANOVA).
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This report has the limitation of all retrospective
analyses: the lack of randomization. The evaluation of a
drug effect is essentially dependent on how patients are
ascertained to the drug or to non-drug groups. However,
observational studies can help understanding associated
effects of drugs, since main bias is carefully considered.
We considered that there were no remarkable differences
between DNP group and Non-DNP group for social
status, such as economic status, or family supports.
Actually the patients were all residents in Tajiri, a typical
agricultural town, where they were born, grew up, and got
married in the same area. All men analyzed were farmers
and all women analyzed were house wives, having similar
life styles. This unique “pure” social status can exclude
possible confounding effects of social factors on life
expectancy.Figure 3 Period of donepezil use and life expectancy in AD.
AD = Alzheimer’s disease. There was a significant Spearman
correlation (Rs = 0.439, p < 0.0001) between the period of donepezil
administration (months, horizontal line) and life expectancy
(months, vertical line).Regarding health status, two groups’ distribution of
vascular risk factors (hypertension, diabetes mellitus,
dyslipidemia, cardiac diseases) were not statistically dif-
ferent (chi-square tests, data not shown). Also, we previ-
ously reported the Quality-Adjusted Life-Year (QUALY)
for various degrees of daily activities of AD [17]; we
herein analyzed the QUALY for the DNP and Non-DNP
groups, and the same results were obtained (data not
shown). Thus we think that although the study has the
limitation, the results can provide useful information on
the life expectancy in AD. The possible reasons for the
positive finding were discussed below.
Cause of death
Knowledge of the causes of death is of value in terminal
care of patients with dementia. Cancer, heart disease,
and stroke are the main causes of death in the whole
Japanese population (the Ministry of Health, Labour and
Welfare 2011 < http://www.mhlw.go.jp/toukei/saikin/hw/
jinkou/suikei10/index.html >), but not in patients with
AD. Stroke and heart diseases are vascular diseases that
are commonly accompanied by VaD, but not by AD. InFigure 4 Donepezil and nursing home effects on life
expectancy in AD. NH = nursing home, AD = AD = Alzheimer’s
disease. The vertical line indicates life expectancy (months). From
the left to right, DNP + NH group, non-DNP + NH group, DNP +
non-NH group, and non-DNP + non-NH group. There were significant
effects of the drug (F = 14.105; p < 0.001) and nursing home residency
(F = 17.326, p < 0.001) without significant interactions (F = 0.894,
p = 0.347). No other covariates reached a significant level (age: F = 0.206,
p = 0.651; gender: F = 0.796, p = 0.375; CVD: F = 2.911, p = 0.091; typical
antipsychotic drugs: F = 0.035, p = 0.852; atypical antipsychotic drugs:
F = 0.362, p = 0.549).
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patients with AD. In cases with clinical and pathological
diagnoses of dementia and a complete autopsy, Brunnström
et al. [18] found that the two most common causes
of death were bronchopneumonia and ischemic heart
disease, while cancer was uncommon. Pneumonia as
an immediate cause of death in dementia may reflect
a terminal stage in which patient care and feeding is
difficult to manage effectively.
Wada et al. [19] found that use of antipsychotics, pres-
ence of CVD in the basal ganglia, severity of dementia,
and male gender were associated with aspiration pneu-
monia in AD. However, our investigation of these factors
did not show these relationships in patients who did and
did not take donepezil (data not shown). Drugs such as
angiotensin-converting enzyme inhibitors improve the
swallowing reflex, thus preventing exacerbation of pneu-
monia [20], but we also found no effect of these drugs
(data not shown). Thus the longer life expectancy in the
DNP group was considered to be due to donepezil itself.
Why does donepezil prolong life expectancy?
As described above, the possible effect of donepezil on
mortality is uncertain. A recent cohort study [19] showed
that donepezil use was associated with a lower risk of
death and myocardial infarction, probably because of the
vagotonic and anti-inflammatory properties of the drug
on atherosclerosis. Given the important actions of ChEIs
on the heart, Sato et al. [21] undertook a retrospective
cohort investigation to assess the effects of donepezil on
cardiovascular mortality. Contrary to the drug action and
the higher risk for sinus node dysfunction or cardiac con-
duction impairment, this analysis showed better cardio-
vascular and overall survival in donepezil-treated patients.
This finding is supported by an animal study showing that
oral donepezil improved survival in a mouse congestive
heart failure model through prevention of pumping failure
and cardiac remodeling [22]. However, in our AD patents,
there was no difference in heart disease between the DNP
and non-DNP groups.
Donepezil may have a negative effect on aspiration
pneumonia due to a side effect of nausea. An increased
gastro-esophageal reflex may induce pneumonia. This
and the absence of an effect on heart disease in our
patients suggest that the effect of donepezil on life ex-
pectancy was not purely pharmacological. Single photon
emission CT studies have shown increased psychomotor
speed or attention function after administration of done-
pezil, associated with frontal, limbic, lower temporal
lobes in the cingulate cortex [23] or frontal and parietal
lobes in the basal ganglia [24]. Stimulation of psycho-
motor speed and attention by donepezil is consistent
with the higher mortality in older adults with lower
perceptual speed [1].The effect of donepezil of delaying progression of AD
may also maintain the “energy level” of life. Patients with
moderate to severe AD show instrumental and basic
activities of daily living (ADL) benefits after donepezil
administration. In a study of the long-term effects of
donepezil on the use of community-based home help
service, Wattmo et al. [25] found that the drug reduced
the use of the service, i.e., maintained higher self-
supported levels of instrumental ADL. Psychosocial
activities may occur more smoothly with maintenance of
ADL, as well as with increased psychomotor speed and
attention. Rehabilitation also has a long-term effect in
decreasing mortality, and especially improves motor dis-
ability and ADL [26] and prevents aspiration pneumonia
[27]. Based on these observations, a prospective longitu-
dinal study is needed to clarify the effects of donepezil
in patients with AD.
Effect of antipsychotics on life expectancy
In recent years, atypical antipsychotic drugs such as
risperidone have largely replaced conventional medica-
tions such as haloperidol due to equal efficacy and better
tolerance [28]. In particular, physicians prefer to prescribe
atypical antipsychotics to patients with dementia. How-
ever, atypical antipsychotics were found to have efficacy
limitations for treatment of BPSD in a double-blind ran-
domized placebo-controlled trial [29].
Such limitations are not the only problem with antipsy-
chotics, since these drugs have a negative effect on life
expectancy [30] and this has led to a discussion of the ap-
propriateness of their use. A large retrospective cohort
study (n = 4,369) [31] showed twofold and fivefold in-
creases in mortality in users of atypical and conventional
antipsychotics, respectively, compared to non-users. Our
results were in contrast to these findings, but this was
probably because the AD patients took only small doses of
antipsychotic drugs (risperidone 1 mg/day, levomeproma-
dine 5 mg/day) for less than 3 months.
Nursing home effect
The effect of nursing home residency should also be
considered. Compared with living at home, better man-
agement of therapy (better drug compliance) and a better
general environment (good temperature and nutrition) in
a nursing home may have a positive effect on life expect-
ancy. However, the similar life expectancies of patients
taking donepezil at home and those who did not receive
donepezil and lived in a nursing home suggests a positive
health economics effect of the drug. In the Long-Term
Care Insurance (LTCI) system in Japan, nursing home
residency costs about 100,000 Yen/month, whereas done-
pezil treatment costs 500 Yen/day, i.e., 15,000 Yen/month.
Thus, use of donepezil at home can significantly reduce
the cost of management of patients with AD.
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Although this report has the limitation of all retrospective
analyses: the lack of randomization, we found a positive
effect of donepezil on lifetime expectancy after onset of
AD. This may be due to a decreased mortality rate caused
by reduction of concomitant diseases such as pneumonia.
The similar life expectancies in patients taking donepezil
at home and those not taking donepezil in a nursing home
indicated a positive health economic effect of the drug.
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